Navigation Links
Neurobiological Technologies, Inc. Reports Fourth Quarter and Fiscal Year-End Financial Results for 2007 Announces 1-for-7 Reverse Stock Split
Date:9/14/2007

ants totaled $980,000 for the year ended June 30, 2007 compared to zero in fiscal year 2006. In April 2007, the Company sold 3,043,478 shares of common stock and warrants and the Company recognized a change in the value of the warrants of $980,000 during the fourth quarter of fiscal year 2007 due to a decline in the Company's stock price during that time.

Bridge Financing

On September 12, 2007, the Company completed a $6.0 million debt and equity bridge financing under its effective shelf registration statement. In the financing, the Company issued $6.0 million in principal amount of 15% senior secured promissory notes due January 15, 2008 and 2,750,000 shares of common stock, which will be subject to certain trading restrictions until January 15, 2008. The Company expects to repay the indebtedness in October 2007 with proceeds from its planned registered public offering.

Reverse Stock Split

On September 12, 2007, the Company received stockholder approval for a reverse split of its outstanding common stock within a range of 1-for-5 to 1-for-7. On September 14, 2007, a committee of the Board approved the implementation of the reverse split at a ratio of 1-for-7. The reverse split will be come effective on Monday, September 17, 2007 and the Company's common stock will begin trading on the NASDAQ Capital Market on a post-split basis that day.

Upon effectiveness of the reverse split, every seven shares of common stock issued and outstanding will be automatically converted into one new share of common stock. Fractional shares that result from the split will not be issued and holders will be paid cash in lieu of fractional shares. The Company's common stock will trade under the symbol "NTIID" for 20 trading days to denote the reverse split. After that time, the symbol will revert to "NTII". Holders of record will receive instructions from American Stock Transfer & Trust Company, the Company's transfer agent, for how to surrender their pre-spl
'/>"/>

SOURCE Neurobiological Technologies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... Continental Clinical Solutions, LLC (Continental) focuses ... at its mid-Atlantic late-phase research facility, located in ... the idea of closing patient disparities in mind. ... advances," said Continental's CEO, Saleh Stevens . ... cell line of Henrietta Lacks, dubious ethical practices ...
(Date:11/23/2014)... November 23, 2014 Apiscent Labs, ... of fine chemical ingredients to the global pharmaceutical ... of its new website, Apiscent.com. , The Apiscent.com ... Labs, clean design, easy navigation, rotating images and ... Labs stand out. , The company’s ...
(Date:11/22/2014)... 2014 RURO, Inc., a leading ... released Limfinity® version 5.1.4. , RURO’s deployment teams ... than ever in RURO’s 8 year history. Many ... enhancement. Limfinity® version 5.1.4 is the perfect example ... bug fixes! , Limfinity® 5.1.4 release highlights – ...
(Date:11/22/2014)...   , ... zu KLOX    Mariano ... Officer bestellt    KLOX ist bestens ... zugelassenen Behandlungssystems zur Wundheilung zu beginnen    , ... sehr erfreut, die folgenden personellen Veränderungen anzukündigen: ...
Breaking Biology Technology:At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 2At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 3RURO Announces Limfinity® version 5.1.4 2KLOX Technologies meldet Neubesetzung von Führungspositionen 2KLOX Technologies meldet Neubesetzung von Führungspositionen 3KLOX Technologies meldet Neubesetzung von Führungspositionen 4KLOX Technologies meldet Neubesetzung von Führungspositionen 5
... Corporation,(NYSE: POL ), a premier provider of ... it has entered into an exclusive,license arrangement for ... Battelle., The global market for plasticizers is ... consumed in vinyl-based formulations.,Specialty plasticizers currently account for ...
... Quarter 2007, EMERYVILLE, Calif., Aug. 5 Onyx,Pharmaceuticals, ... results,for the three and six months ended June 30, ... per diluted share, for the second quarter of 2008,compared ... per diluted share, in the,same period in 2007. Excluding ...
... - Atrium Innovations Inc.,(TSX: ATB), a recognized leading ... products for the health and,nutrition industries, today announced ... Fitzgibbon, will present a company overview,at the upcoming ... August 12, 2008 at 11 am (eastern time), ...
Cached Biology Technology:PolyOne Corporation Announces an Exclusive License Agreement with Battelle for Bio-Plasticizer Technology 2Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results 2Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results 3Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results 4Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results 5Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results 6Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results 7Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results 8Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results 9Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results 10
(Date:11/10/2014)... shelves in early 2010, and people have used them ... be tossed into a washing machine without ever having ... though, has come with risks for young children. , ... found that from 2012 through 2013, U.S. poison control ... years of age swallowing, inhaling, or otherwise being exposed ...
(Date:11/6/2014)... from a team of Florida State University biologists could ... adapt to and survive environmental swings such as droughts ... issue of the journal The Plant Cell , ... and proteins) is organized in a cell and how ... turned on and others are turned off. , "If ...
(Date:11/5/2014)... associate professor of biology in the UTSA College ... the nation selected to receive a two-year $300,00 ... Exploratory Research (EAGER). The funding supports President Obama,s ... to create new technology that will demystify complex ... behaviors in neuroscience are broken into the interactions ...
Breaking Biology News(10 mins):Study finds laundry detergent pods, serious poisoning risk for children 2Maize analysis yields whole new world of genetic science 2UTSA biology professor awarded $300,000 NSF grant for brain research 2UTSA biology professor awarded $300,000 NSF grant for brain research 3
... ever European-wide retrospective analysis presented today at the International ... to be effective treatments, providing positive survival rates in ... , Wilson disease is a rare genetic storage disorder ... effectively, leading to excess copper build up, liver failure ...
... investigation of the Tigris-Euphrates delta in 20 years was ... explore the links between wetland resources and the emergence ... in Iraq stopped in the 1990s," said Carrie Hritz, ... but because their work is unpublished, we are unsure ...
... Davis cancer researchers have found that older men with ... CT scans over lymph node removal are at greater ... week in the journal Cancer, indicate that physicians should ... discussing treatment options with their patients. Along ...
Cached Biology News:European-wide study confirms benefits of D-penicillamine and trientine for Wilson disease 2Archaeologists explore Iraqi marshes for origins of urbanization 2Frequent CT scanning for testicular cancer surveillance associated with secondary malignancies 2Frequent CT scanning for testicular cancer surveillance associated with secondary malignancies 3
... Error-free cloning of BAC (100+kb), fosmid (40kb), ... insert stability than any othe BAC vector. ... high yields and easy recombinant DNA purification. ... transcription-free (pSMART VC) vectors for the highest ...
...
... Adapted to Sf-900 ... were isolated from Spodoptera ... insect cells (1). The ... to serum-free suspension culture ...
6-carboxy-2',4,4',5',7,7'-hexachlorofluorescein, succinimidyl ester (6-HEX, SE) *single isomer*...
Biology Products: